San Diego, CA—Data presented at the American Society of Hematology suggest that the antibody conjugate drug, gemtuzumab ozogamicin (Mylotarg; Pfizer)—once approved for use in acute myeloid leukemia (AML) in 2000, and then voluntarily pulled from the market in 2010 due to post-marketing evidence of lack of efficacy, as well as unacceptable toxicity—may have a shot [...]
The Cancer Center Business Summit (http://www.CancerBusinessSummit.com) is a nationally recognized educational resource which deals with oncology/cancer care delivery, oncologist-hospital alignment and integration, and the business, legal, and financial models associated with such initiatives. Each year, in conjunction with its annual conference, the Summit conducts a research survey of current trends affecting the oncology/cancer care sector. [...]
OBR green is our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register to begin receiving OBR green today. View the Most Recent Issue»
